Aarti Drugs Limited Buyback 2023 – Letter of Offer, Record Date, Buyback Price

Aarti Drugs Limited announces a share repurchase program. Under the program, the company will repurchase up to 665,000 shares, with a face value of Rs. 10, representing 0.72% for INR 59.85 Cr. The shares will be repurchased at a price of INR 900 per share. Aarti Drugs Limited Buyback 2023 offer has already been started from August 9th and it closes on 17th August, 2023.

Incorporated in 1984, Aarti Drugs Limited specializes in the production of specialty chemicals and bulk drugs. Their extensive range comprises over 40 products, including bulk actives, key intermediates, and specialty chemicals. These products cover therapeutic groups such as antibiotic, anti-protozoal, anti-inflammatory, anti-fungal, anti-diabetic, cardio-protectant, vitamins, anti-arthritis, and sedatives, addressing critical and lifestyle-related illnesses.

Aarti Drugs operates nine manufacturing units in Tarapur (Maharashtra) and two units in Sarigam (Gujarat), most of which are GMP certified. The company exports to more than 100 countries, holding approvals from multiple authorities like WHO-GMP, ACCREDITATION from JAPAN, IDL China, ANVISA, TGA Australia, COFEPRIS, and COS.

In recent years, Aarti Drugs achieved total revenues of ₹2,71,824.75 lakhs (2023), ₹2,49,996.17 lakhs (2022), and ₹2,15,930.50 lakhs (2021).

Aarti Drugs Limited Buyback 2023 – Offer Details

Offer Type	Tender Offer
Record Date	August 4, 2023
Buyback Starts	August 09, 2023
Buyback Ends	August 17, 2023
Number of Shares	665,000 Equity Share
Face Value	Rs. 10/-
Buyback Price	Rs. 900 per equity shares
Maximum Buyback Size	Rs. 59.85 Crore
Last date for the extinguishment of equity	September 04, 2023
Broker of the company	Ghalla Bhansali Stock Brokers Private Limited
Designated Stock Exchange	NSE, BSE

Aarti Drugs Limited Buyback 2023 – Necessity of the Buyback

The Company’s proposed Buyback serves the following purposes:

Returning excess cash to Equity Shareholders.
Enhancing return on equity and earnings per share through cash distribution and reduction of equity base, thereby increasing shareholder value over the long term.
Offering Equity Shareholders a choice: sell shares for cash or retain shares and enjoy a higher percentage ownership after the Buyback, without additional investment.
Implemented through a tender offer as per Buyback Regulations, the Buyback includes a minimum 15% reservation for Small Shareholders. Additionally, a higher number of shares will be allocated based on entitlement or 15% of shares to be bought back, specifically reserved for Small Shareholders. This approach aims to benefit a significant number of public shareholders, classified as Small Shareholders.

Aarti Drugs Limited Buyback – Shareholding Pattern

Click here to see the shareholding pattern of Aarti Drugs Limited.

Aarti Drugs Limited Buyback – Company Financials

Click here to see the consolidated and standalone financial report of the company.

Aarti Drugs Limited Buyback 2023 – Manager of the Buyback

Manager to this buyback offer by Aarti Drugs Limited is Inga Ventures Pvt Ltd.

Aarti Drugs Limited Buyback 2023 – Registrar of the Buyback

Registrar to this buyback offer by Aarti Drugs Limited is Link Intime India Private Ltd